Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 314

1.
2.

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.

Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, Zhang J, Liu T.

BMC Cancer. 2008 Dec 6;8:363. doi: 10.1186/1471-2407-8-363.

3.
4.

Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.

Mueller RE, Parkes RK, Andrulis I, O'Malley FP.

Genes Chromosomes Cancer. 2004 Apr;39(4):288-97.

PMID:
14978790
5.

Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.

Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS.

Lab Invest. 2008 May;88(5):491-503. doi: 10.1038/labinvest.2008.19. Epub 2008 Mar 10.

6.

Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.

Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M.

Neoplasma. 2006;53(5):393-401.

PMID:
17013533
7.

Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.

Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.

Breast. 2008 Oct;17(5):506-11. doi: 10.1016/j.breast.2008.03.007. Epub 2008 May 5.

PMID:
18456496
8.

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.

Konecny GE, Pauletti G, Untch M, Wang HJ, Möbus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Jänicke F, Slamon DJ.

Breast Cancer Res Treat. 2010 Apr;120(2):481-9. doi: 10.1007/s10549-010-0744-z. Epub 2010 Feb 4.

PMID:
20130985
9.

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.

Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):146-51.

10.

Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.

Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS.

Breast Cancer Res Treat. 2007 Dec;106(2):181-9. Epub 2007 Jan 27.

PMID:
17260090
11.

Gene copy mapping of the ERBB2/TOP2A region in breast cancer.

Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, O'Hare A, Van Stedum SC, Proffitt JH, Seelig SA, Coon JS.

Genes Chromosomes Cancer. 2004 May;40(1):19-31.

PMID:
15034864
12.

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.

Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C.

Acta Oncol. 2006;45(5):590-6.

PMID:
16864174
13.
14.

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. Review.

15.

Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.

Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM.

Breast Cancer Res Treat. 2006 Aug;98(3):337-42. Epub 2006 Feb 24.

PMID:
16502015
16.

Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer.

Moelans CB, de Weger RA, van Blokland MT, van der Wall E, van Diest PJ.

Mod Pathol. 2010 Jan;23(1):62-70. doi: 10.1038/modpathol.2009.136. Epub 2009 Sep 18.

17.

Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.

Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O'Leary JJ, Sheils O.

Cancer Res. 2007 Mar 15;67(6):2893-8.

18.

Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.

Neoplasia. 2014 Oct 23;16(10):861-7. doi: 10.1016/j.neo.2014.08.012. eCollection 2014 Oct.

19.
20.

Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes.

Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schönau A, Overgaard J; Danish Breast Cancer Co-operative Group.

Acta Oncol. 2004;43(1):35-42.

PMID:
15068318

Supplemental Content

Support Center